ZARS Pharma, Inc. operates as a specialty pharmaceutical company that focuses on developing and commercializing topically administered drugs using its proprietary drug delivery technologies, primarily in the area of pain management. It is developing a portfolio of proprietary products and product candidates based on its Controlled Heat-Assisted Drug Delivery and phase-changing cream technologies. The company’s products include Pliaglis, a topical anesthetic cream for dermal anesthesia prior to painful cosmetic procedures, such as laser surgery and dermal filler injections; and Synera, a topical patch for providing dermal analgesia for potentially painful superficial procedures, such as venous access procedures involving needles and immunization injections of children. Its products also comprise ThermoProfen, which is entering into Phase 3 clinical trials for the treatment of mild to moderate chronic pain associated with osteoarthritis of the knee; and Ketoprofen DuraPeel, a Phase 1 clinical trial product for the treatment of acute musculoskeletal pain resulting from soft tissue injuries, such as muscle strains, ankle sprains, and sports injuries. In addition, the company is developing the Alprazolam Patch, which is in Phase 1 clinical trial, for the treatment of panic disorder. The company was formerly known as ZARS, Inc. and changed its name to ZARS Pharma, Inc. in July, 2007. The company was founded in 1996 and is based in Salt Lake City, Utah.

TRANSGENE S.A. company was founded in 1979 and is based in Strasbourg, France. Transgene S.A. is a subsidiary of Merieux Alliance. Transgene S.A., a biopharmaceutical company, engages in the discovery and development of gene-based therapeutic vaccines and immunotherapy products for the treatment of cancer and infectious diseases. The company’s products primarily include TG 4001/R3484, an immunotherapy targeting anti-infectious for human papilloma virus-associated pathologies, which completed Phase IIa trials; TG 4010, a cancer vaccine primarily for non small cell lung cancer, which is in Phase IIb trials; TG 1042, an immune enhancement gene therapy for cutaneous B-cell lymphoma, which is in Phase II trials; TG 4040, an anti-infectious therapeutic vaccine for chronic hepatitis C infection, which is in Phase I trials; and TG 4023, a preclinical suicide gene candidate for the treatment of 5-FU-sensitive tumors. It also offers a package of services relating to molecular biology, development, and biomanufacturing that include design and construction of new vaccines; development and/or adaptation of production process; development and/or adaptation of quality control assays; production and control of starting material for pharmaceutical and clinical development; and manufacturing material for clinical trials. Transgene S.A. has collaboration agreements with Roche, Association Francaise contre les Myopathies, and MIRUS; manufacturing and subcontracting agreements with International AIDS Vaccine Initiative, Innogenetics, Agence Nationale de Recherche contre le SIDA, Institut National de la Sante et de la Recherche Medicale, and EUROVACC; and licensing agreements with Merck, Imperial Cancer Research Technology, Ajinomoto, Aventis, and Cayla.

AES Laboratoire produces and distributes a complete range of microbial testing instruments and equipment. Whether for quality assurance or national security, clients from 21 countries in industries from food production to pharmaceuticals contract with AES to assure the quality and safety of products and to monitor possible hazards in various working environments. AES is developing and patenting technologies that are more accurate and less time-consuming than traditional laboratory testing methods, including machines that sample the air for bio-contaminants and chemical "litmus tests" that can quickly detect and identify pathogens.

CombinatoRx, Incorporated company was founded in 2000 and is based in Cambridge, Massachusetts. CombinatoRx, Incorporated (CombinatoRx) is a biopharmaceutical company focused on developing synergistic combination pharmaceuticals. The Company has devoted substantially all of its resources to the development of its drug discovery technology and the research and development of its drug candidates, including conducting preclinical and clinical trials and seeking intellectual property protection for its technology and product candidates. It has been advancing a portfolio of four product candidates, Synavive (CRx-102), CRx-401, CRx-191 and CRx-197, through clinical research and development, and has a number of product candidates that have either completed Phase IIa clinical trials or are in preclinical development. Its portfolio of clinical product candidates targets multiple diseases including immuno-inflammatory diseases, metabolic disease, chronic pain and topical dermatoses. In December 2009, CombinatoRx and Neuromed Pharmaceuticals Inc. announced that they have merged.

Laboratorios Farmacéuticos ROVI manufactures and sells pharmaceuticals in Spain and the rest of Europe. Its best selling prescription drugs include Hibor, (a brand name heparin used to prevent blood clots during surgery), osteoporosis drug Osseor, and angina drug Corlentor. ROVI's handful of OTC products include Autan insect repellant and the Enerzona line of dietary wellness products.In 2009 the company licensed Novavax's VLP vaccine technology which it will use to create a flu vaccine for the Spanish government. The E60 million ($84 million) program is being sponsored by the Spanish Ministry of Health. ROVI was founded in 1946 and went public on the Spanish Stock Exchange in late 2007.

Advanced Vision Research, Inc. company makes TheraTears, a line of over-the-counter eye drops developed to treat dry eye, a condition caused by aging, contact lens wear, sun, or wind. TheraTears are designed to imitate human tears, keeping eyes moist and allowing the surface of the eye to absorb oxygen and other needed nutrients. Other products include a TheraTears version for contact lens-wearers, an Omega-3-infused version to promote eye health, and an eyelid cleanser. Advanced Vision's products are made by Akorn's contract manufacturing unit and are sold through global retail outlets. TheraTears was developed by the late founder and former CEO Jeffrey Gilbard.

Athersys, Inc., is a biopharmaceutical company engaged in the discovery and development of therapeutic products. Through the application of its technologies, the Company has established a pipeline of therapeutic product development programs in multiple disease areas. The Company’s current product development portfolio consists of MultiStem, a patented and stem cell product that the Company is developing as a treatment for multiple disease indications, and that is being evaluated in two ongoing clinical trials. In addition, the Company are developing novel pharmaceuticals to treat indications such as obesity, certain cognitive and attention disorders, narcolepsy or other forms of excessive daytime sleepiness. In December 2008, the Company were granted authorization by the United States Food and Drug Administration (FDA), to initiate a third clinical trial, administering MultiStem for the treatment of ischemic stroke.

Clinimetrics Research Associates, Inc. company is a contract research organization (CRO) that provides clinical research services, consulting, project management, data management, and electronic data capture services through most stages of clinical trials. Its services aim to control costs for customers including global biotechnology, pharmaceutical, and medical device companies. It specializes in biotech development, as well as in therapeutic areas such as oncology and cardiology research. Clinimetrics has locations throughout North America. The company is a subsidiary of institutional pharmacy operator Omnicare.

The German drug company -- seller of popular over-the-counter remedies Zantac and Dulcolax, as well as prescription Flomax for enlarged prostate -- makes a host of prescription and OTC products, not to mention fine chemicals and pet medications. Its prescription drugs include treatments for respiratory ailments, hypertension, HIV, and depression. Boehringer also offers cold, gastrointestinal, and pain remedies, as well as vaccines, drugs, and nutritionals for farm animals and pets. The company operates worldwide. The founding Boehringer family controls the company through parent company C.H. Boehringer Sohn.

Lipoxen Plc, a biopharmaceutical company, develops drug and vaccine delivery systems, and proprietary products in the fields of protein drugs, vaccines, and oncology. The company’s product candidates under development include ErepoXen for the treatment to maintain the red blood cell population and prevent anaemia; StimuXen for the treatment of neutropenia; InferoXen for hepatitis C; SuliXen for the treatment of type II diabetes; LipoNeu for streptococcus pneumoniae; LipoTet, an oral liposomal tetanus vaccine; HepaXen to prevent and treat hepatitis B; LipoRab, a rabies vaccine candidate; and LipoTaxen, an anti-cancer drug for the treatment of lung, breast, ovarian, and other cancers. It has operations in the United States, Europe, and India. Lipoxen Plc has a collaboration agreement with Pharmsynthez JSC. The company is based in London, the United Kingdom.

Inviting Real Estate Agents, Job Placements Agents, Educational Institutes, Software Service Providers, Real Estate Builders, Marriage Bureaus, Travel Agents, Restaurant Owners, Health & Fitness Centers and other Local Businesses to Post a FREE Classified Advertisement on Cootera.com Classifieds Website.